Abstract
| Original language | English |
|---|---|
| Article number | 107619 |
| Journal | iScience |
| Volume | 26 |
| Issue number | 9 |
| DOIs | |
| Publication status | Published - 15 Sept 2023 |
Keywords
- Glycomics
- Immune response
- Immunology
- Microbiology
Access to Document
Other files and links
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: iScience, Vol. 26, No. 9, 107619, 15.09.2023.
Research output: Contribution to journal › Article › Academic › peer-review
TY - JOUR
T1 - Comparative analysis of spike-specific IgG Fc glycoprofiles elicited by adenoviral, mRNA, and protein-based SARS-CoV-2 vaccines
AU - Radboud University Medical Center (RUMC) and COUGH1 study group
AU - van Coillie, Julie
AU - Pongracz, Tamas
AU - Šuštić, Tonći
AU - Wang, Wenjun
AU - Nouta, Jan
AU - le Gars, Mathieu
AU - Keijzer, Sofie
AU - Linty, Federica
AU - Cristianawati, Olvi
AU - Keijser, Jim B. D.
AU - Visser, Remco
AU - in collaboration with the UMC COVID-19 S3/HCW study group
AU - van Vught, Lonneke A.
AU - Slim, Marleen A.
AU - van Mourik, Niels
AU - Smit, Merel J.
AU - Sander, Adam
AU - Schmidt, David E.
AU - Steenhuis, Maurice
AU - Rispens, Theo
AU - Nielsen, Morten A.
AU - Mordmüller, Benjamin G.
AU - Vlaar, Alexander P. J.
AU - Ellen van der Schoot, C.
AU - Roozendaal, Ramon
AU - Wuhrer, Manfred
AU - Vidarsson, Gestur
AU - Appelman, Brent
AU - van de Beek, Diederik
AU - Bomers, Marije K.
AU - de Brabander, Justin
AU - Brouwer, Matthijs C.
AU - Buis, David T. P.
AU - Chekrouni, Nora
AU - van Gils, Marit J.
AU - de Jong, Menno D.
AU - Lavell, Ayesha H. A.
AU - Olie, Sabine E.
AU - Peters, Edgar J. G.
AU - Reijnders, Tom D. Y.
AU - Schinkel, Michiel
AU - Schuurman, Alex R.
AU - Sikkens, Jonne J.
AU - Smulders, Yvo M.
AU - Wiersinga, Joost W.
AU - Fatebenefratelli-Sacco Infectious Diseases Physicians group
AU - Spinello, Antinori
AU - Bassoli, Cinzia
AU - Bestetti, Giovanna
AU - Corbellino, Mario
AU - Covizzi, Alice
AU - Lupo, Angelica
N1 - Funding Information: We thank the Academic Medical Centre of the University of Amsterdam, the Sanquin Blood Supply Foundation, Janssen Vaccines and Prevention B.V. and Radboud University Medical Center (RUMC) & Bavarian Nordic A/S. We furthermore thank all cohort participants, to whom we are greatly indebted for their extensive participation. Funding: Landsteiner foundation for Blood Transfusion Research (LSBR) grants 1721 and 1908 (G.V.). ZonMW COVID-19 grant 1043001 201 0021 (G.V.). Netherlands Organization for Health Research and Development ZonMw & the Amsterdam UMC Corona Research Fund (Amsterdam UMC COVID-19 S3/HCW study group). The Netherlands Organisation for Health Research and Development ZonMW VENI grant, grant number 09150161910033 (L.A.V.V.). Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic [H2020-SC1-PHE-CORONAVIRUS-2020 grant agreement ID: 101003608 ] (M.W.). Semper Ardens Carlsberg Foundation (M.W.). This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the United States Department of Health and Human Services or its components. Conceptualization: G.V. M.W. C.E.v.d.S. A.V. and D.E.S. Methodology: G.V. M.W. J.V.C. T.P. and T.S. Formal analysis: J.V.C. T.P. T.S. and S.K. Investigation: J.V.C. T.S. T.P. S.K. M.S. F.L. R.V. W.W. and J.N. Resources: D.S. L.A.v.V. W.H. M.A.S. R.M. M.K.B. J.J.S. A.S. D.S. M.A.N. B.G.M. R.R. M.L.G. and the UMC COVID-19 S3/HCW study group, Fatebenefratelli-Sacco Infectious Diseases Physicians group and Radboud University Medical Center (RUMC) & Bavarian Nordic (BN) A/S. Data curation: J.V.C. T.S. T.P. S.K. and M.S. Writing – Original draft: G.V. M.W. J.V.C. T.P. and R.R. Writing – Review and editing: J.V.C. T.P. T.S. W.W. J.N. M.L.G. S.K. F.L. O.C. J.B.D.K. R.V. L.A.v.V. M.A.S. N.v.M. M.J.S. A.S. D.E.S. M.S. T.R. M.A.N. B.G.N. A.P.J.V. C.E.v.d.S. R.R. M.W. and G.V. Visualization: T.P. and J.V.C. Supervision: G.V. M.W. A.V. and R.R. Project administration: G.V. M.W. and M.S. Funding acquisition: G.V. M.W. T.P. and Radboud University Medical Center (RUMC) & COUGH1. M.L.G. and R.R. are employees of Janssen Pharmaceuticals and M.L.G. is a shareholder in Johnson & Johnson. A.S. and W.A.d.J. are employees at AdaptVac, a company commercializing virus-like particle display technology and vaccines, including several patents. A.S. A.S. T.G.T. and M.N. are founders of AdaptVac and listed as coinventors on a patent covering the AP205 CLP vaccine platform technology (WO2016112921 A1) licensed to AdaptVac. Janssen Pharmaceuticals sponsored IgG glycosylation analysis at LUMC. Sanquin provided consultancy services to Janssen Pharmaceuticals during this study. All other authors declare they have no conflicts of interests. Funding Information: Funding: Landsteiner foundation for Blood Transfusion Research (LSBR) grants 1721 and 1908 (G.V.). ZonMW COVID-19 grant 1043001 201 0021 (G.V.). Netherlands Organization for Health Research and Development ZonMw & the Amsterdam UMC Corona Research Fund (Amsterdam UMC COVID-19 S3/HCW study group). The Netherlands Organisation for Health Research and Development ZonMW VENI grant, grant number 09150161910033 (L.A.V.V.). Advancing knowledge for the clinical and public health response to the 2019-nCoV epidemic [H2020-SC1-PHE-CORONAVIRUS-2020 grant agreement ID: 101003608 ] (M.W.). Semper Ardens Carlsberg Foundation (M.W.). This project has been funded in whole or in part with federal funds from the Department of Health and Human Services, Administration for Strategic Preparedness and Response, Biomedical Advanced Research and Development Authority, under Other Transaction Agreement HHSO100201700018C. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the United States Department of Health and Human Services or its components. Publisher Copyright: © 2023 The Author(s)
PY - 2023/9/15
Y1 - 2023/9/15
N2 - IgG antibodies are important mediators of vaccine-induced immunity through complement- and Fc receptor-dependent effector functions. Both are influenced by the composition of the conserved N-linked glycan located in the IgG Fc domain. Here, we compared the anti-Spike (S) IgG1 Fc glycosylation profiles in response to mRNA, adenoviral, and protein-based COVID-19 vaccines by mass spectrometry (MS). All vaccines induced a transient increase of antigen-specific IgG1 Fc galactosylation and sialylation. An initial, transient increase of afucosylated IgG was induced by membrane-encoding S protein formulations. A fucose-sensitive ELISA for antigen-specific IgG (FEASI) exploiting FcγRIIIa affinity for afucosylated IgG was used as an orthogonal method to confirm the LC-MS-based afucosylation readout. Our data suggest that vaccine-induced anti-S IgG glycosylation is dynamic, and although variation is seen between different vaccine platforms and individuals, the evolution of glycosylation patterns display marked overlaps.
AB - IgG antibodies are important mediators of vaccine-induced immunity through complement- and Fc receptor-dependent effector functions. Both are influenced by the composition of the conserved N-linked glycan located in the IgG Fc domain. Here, we compared the anti-Spike (S) IgG1 Fc glycosylation profiles in response to mRNA, adenoviral, and protein-based COVID-19 vaccines by mass spectrometry (MS). All vaccines induced a transient increase of antigen-specific IgG1 Fc galactosylation and sialylation. An initial, transient increase of afucosylated IgG was induced by membrane-encoding S protein formulations. A fucose-sensitive ELISA for antigen-specific IgG (FEASI) exploiting FcγRIIIa affinity for afucosylated IgG was used as an orthogonal method to confirm the LC-MS-based afucosylation readout. Our data suggest that vaccine-induced anti-S IgG glycosylation is dynamic, and although variation is seen between different vaccine platforms and individuals, the evolution of glycosylation patterns display marked overlaps.
KW - Glycomics
KW - Immune response
KW - Immunology
KW - Microbiology
UR - http://www.scopus.com/inward/record.url?scp=85169841393&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.isci.2023.107619
DO - https://doi.org/10.1016/j.isci.2023.107619
M3 - Article
C2 - 37670790
SN - 2589-0042
VL - 26
JO - iScience
JF - iScience
IS - 9
M1 - 107619
ER -